INOVIO to Showcase DNA Medicine Breakthroughs for Hemophilia A at WFH Congress
Event summary
- INOVIO will present data on its DNA-encoded protein (DPROT) technology for hemophilia A at the World Federation of Hemophilia World Congress on April 22, 2026.
- Key presentation will demonstrate in vivo production of functional FVIII in mouse models using non-viral vector DNA medicine platform.
- Poster session will highlight efficacious FVIII protein levels and correction of bleeding phenotype in hemophilia A mice.
- Abstracts from presentations will be published on INOVIO's website post-event.
The big picture
INOVIO's presentation at the WFH Congress represents a strategic pivot into rare disease therapeutics, expanding beyond its core focus on HPV and infectious diseases. The company's DNA medicine approach aims to address the unmet need for more sustainable treatments in hemophilia A, potentially disrupting the current market dominated by protein replacement therapies. Success in this area could significantly broaden INOVIO's therapeutic pipeline and commercial opportunities.
What we're watching
- Clinical Translation
- How quickly INOVIO can advance from mouse model success to human clinical trials for hemophilia A treatment.
- Technology Validation
- Whether the DPROT technology can demonstrate similar efficacy in larger animal models or human studies.
- Competitive Positioning
- The pace at which INOVIO can establish its DNA medicine platform as a viable alternative to existing hemophilia treatments.
Related topics